DAPA-HF tested dapagliflozin in patients with HFrEF, including individuals with and without diabetes. The randomized trial showed that adding dapagliflozin to standard therapy significantly reduced the composite of worsening heart failure or cardiovascular death compared with placebo. Importantly, the benefit was observed irrespective of diabetes status, reinforcing the concept that SGLT2 inhibition has become a heart-failure therapy rather than a diabetes-only intervention. For general physicians, this is especially relevant because many HFrEF patients are managed across internal-medicine and cardiology interfaces. The treatment decision should therefore be integrated into a broader GDMT pathway that also addresses renin–angiotensin system blockade, beta-blockade and mineralocorticoid receptor antagonism. Adverse effects, volume status, renal function and the patient's ability to maintain therapy should be considered. The DAPA-HF findings also illustrate the modern shift from treating isolated risk factors to targeting disease pathways that influence hospitalization and survival. In practice, the challenge is often not identifying evidence-based agents but initiating them early, titrating when tolerated and coordinating follow-up so that the patient receives the full therapeutic benefit.